Mirae Asset Global Investments Co. Ltd. Buys 245,665 Shares of Merck & Co., Inc. $MRK

Key Points

• Mirae Asset increased its Merck position by 13.7%, purchasing 245,665 shares to hold 2.03 million shares valued at approximately $261.25 million. Institutional investors collectively own about 76.07% of MRK.
• Analyst sentiment remains favorable: Merck has a “Moderate Buy” consensus rating, with 15 Buy ratings and seven Holds, and a consensus price target of $135.50. Recent targets range from $142 to $155.
• Merck exceeded quarterly revenue and earnings expectations, reporting $16.61 billion in revenue and 5.1% year-over-year growth, while declaring a $0.85 quarterly dividend. However, executives have sold shares recently, and future Keytruda patent expirations remain a key risk.

Mirae Asset Global Investments Co. Ltd. lifted its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 13.7% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,033,072 shares of the company's stock after buying an additional 245,665 shares during the period. Mirae Asset Global Investments Co. Ltd. owned approximately 0.08% of Merck & Co., Inc. worth $261,250,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Kingdom Financial Group LLC. purchased a new stake in Merck & Co., Inc. during the fourth quarter valued at approximately $25,000. Abound Financial LLC purchased a new position in Merck & Co., Inc. in the fourth quarter worth $26,000. Prosperity Bancshares Inc purchased a new position in Merck & Co., Inc. in the fourth quarter worth $26,000. High Note Wealth LLC increased its position in shares of Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company's stock worth $31,000 after purchasing an additional 109 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. acquired a new position in shares of Merck & Co., Inc. during the fourth quarter worth $31,000. Hedge funds and other institutional investors own 76.07% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Scotiabank raised their price objective on Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a "sector outperform" rating in a research report on Tuesday, June 30th. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $142.00 target price on shares of Merck & Co., Inc. in a research report on Wednesday, July 8th. Guggenheim upped their target price on Merck & Co., Inc. from $145.00 to $146.00 and gave the company a "buy" rating in a research report on Wednesday, August 5th. Daiwa Securities Group upgraded Merck & Co., Inc. from a "neutral" rating to an "outperform" rating and set a $143.00 price target for the company in a research note on Wednesday. Finally, Wells Fargo & Company raised their price target on Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an "overweight" rating in a report on Wednesday, July 8th. Fifteen research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $135.50.

Insider Activity

In other Merck & Co., Inc. news, EVP Jennifer Zachary sold 80,315 shares of the firm's stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the completion of the transaction, the executive vice president directly owned 45,509 shares of the company's stock, valued at approximately $6,073,631.14. This trade represents a 63.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP David Michael Williams sold 52,847 shares of the firm's stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the transaction, the executive vice president directly owned 31,716 shares of the company's stock, valued at $4,084,069.32. This represents a 62.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is owned by insiders.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst upgrade and higher valuations: Daiwa Securities upgraded MRK from “neutral” to “outperform” and set a $143 price target. Other analysts have raised fair-value estimates into the $140–$155 range, citing pipeline progress, business-development activity and late-stage therapies. Daiwa Securities upgrade
• Positive Sentiment: Business momentum remains supportive: MRK recently touched a record high, while Keytruda demand, oncology products, new launches and Animal Health helped drive quarterly revenue of $16.61 billion, above the $16.37 billion consensus estimate. The company also exceeded earnings expectations and reported 5.1% year-over-year revenue growth. Merck fair value and pipeline progress
• Positive Sentiment: Income and diversification appeal: Merck declared its regular $0.85 quarterly dividend, or $3.40 annualized, while potential expansion of ENFLONSIA for RSV prevention could broaden growth beyond oncology.
• Neutral Sentiment: Insider selling warrants monitoring: EVP Chirfi Guindo sold 10,000 shares for $1.35 million, following substantial sales by executives Jennifer Zachary and Richard Deluca. Each executive retained a meaningful stake, so the transactions may reflect personal financial decisions rather than a deteriorating outlook. Merck insider selling report
• Negative Sentiment: Keytruda concentration is a future risk: Patent expiration and increasing competition could pressure Merck’s largest growth driver. Investors will need evidence that the pipeline and newer products can offset eventual Keytruda sales declines. Keytruda growth outlook

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $135.78 on Friday. The firm has a market capitalization of $334.98 billion, a price-to-earnings ratio of 108.62, a price-to-earnings-growth ratio of 5.86 and a beta of 0.19. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.06. The business has a fifty day moving average of $125.54 and a 200 day moving average of $119.94. Merck & Co., Inc. has a 1 year low of $77.58 and a 1 year high of $135.97.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.13. The company had revenue of $16.61 billion during the quarter, compared to analysts' expectations of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The firm's revenue was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, research analysts expect that Merck & Co., Inc. will post 2.77 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.5%. Merck & Co., Inc.'s payout ratio is 272.00%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source